Eli Lilly and Company (NYSE: LLY) on Tuesday reported higher earnings and revenues for the third quarter of 2022. The company also provided guidance for fiscal 2022.
The Indianapolis-based pharmaceutical company said its revenues moved up 2% year-over-year to $6.94 billion in the third quarter as worldwide volumes increased by 13%.
The positive top-line performance translated into a 12% increase in net earnings, on an adjusted basis, to $1.98 per share. Unadjusted profit increased to $1.45 billion or $1.61 per share from $1.11 billion or $1.22 per share in the third quarter of 2021.
Check this space to read management/analysts’ comments on Eli Lilly’s Q3 2022 earnings
“With four more launches expected by the end of next year and a potential major new indication for tirzepatide, Lilly continues to make progress for patients with unaddressed medical needs through our significant commitment to invest in R&D, welcome the best talent, and turn breakthroughs in our labs into medicines for people around the world,” said David Ricks, CEO of Eli Lilly.
